Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07211438

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Centre for Addiction and Mental Health · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.

Detailed description

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression.

Conditions

Interventions

TypeNameDescription
DRUGPsilocybin25 mg Psilocybin

Timeline

Start date
2026-04-01
Primary completion
2028-04-01
Completion
2028-12-01
First posted
2025-10-08
Last updated
2026-03-18

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT07211438. Inclusion in this directory is not an endorsement.